Volume 29, No 6, Jun 2019
ISSN: 1001-0602
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 29 Issue 6, June 2019: 427-428
RESEARCH HIGHLIGHTS
Treating leukemia: differentiation therapy for mIDH2 AML
Xiao-Jian Sun1 , Sai-Juan Chen1 and Zhu Chen1
1State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China
Correspondence: Xiao-Jian Sun (xjsun@sibs.ac.cn) or Sai-Juan Chen (sjchen@stn.sh.cn)
While the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL) has been a remarkably successful example for differentiation therapy of cancer, the recently developed therapeutics of mutant IDH2 (mIDH2)-associated leukemia by specific mIDH2 inhibitors is launching another promising campaign. Interestingly, a recent study in Cell Research by Mugoni et al. demonstrated a sensitivity of the mIDH2 leukemia to the APL-like ATRA/ATO combination therapy, narrating a convergence of two tales.
https://doi.org/10.1038/s41422-019-0173-4
FULL TEXT | PDF
Browse 806
